These data show that AU-011, a first in class VDC, in combination with immune checkpoint inhibition is effective against both primary tumors and distant metastases in a preclinical model
Webcast of the Cowen fireside chat and Jefferies presentation will be available on Aura's “Investors & Media” page
Kala Will Receive $60 Million in Upfront Payment; Eligible to Receive Additional Sales-Based Milestone Payments
Findings provide additional preclinical validation ahead of IND/CTA submission planned in Q3 2022
• LAVA-1207 Phase 1/2a trial in metastatic castration-resistant prostate cancer dosed the first patients and is on track to report initial data in H2 2022
We continue to advance the AU-011 overall development program and look forward to several upcoming clinical milestones, in the second half of this year
Supported by encouraging preclinical and preliminary clinical data, we believe in the potential of LAVA-051 to address unmet patient needs.
Heart failure patients implanted with Barostim can now receive conditional MRI scans
Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer
demonstrating a highly significant protection of visual function as well as greater cone density following subretinal administration of SPVN06 in a murine model.
Subscribe to our weekly newsletter for the latest updates on life sciences investments.